Published in

Wiley, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023

DOI: 10.1002/alz.13161

Links

Tools

Export citation

Search in Google Scholar

Predicting amyloid‐beta pathology in the general population

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractINTRODUCTIONReliable models to predict amyloid beta (Aβ) positivity in the general aging population are lacking but could become cost‐efficient tools to identify individuals at risk of developing Alzheimer's disease.METHODSWe developed Aβ prediction models in the clinical Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study (n = 4,119) including a broad range of easily ascertainable predictors (demographics, cognition and daily functioning, health and lifestyle factors). Importantly, we determined the generalizability of our models in the population‐based Rotterdam Study (n = 500).RESULTSThe best performing model in the A4 Study (area under the curve [AUC] = 0.73 [0.69–0.76]), including age, apolipoprotein E (APOE) ε4 genotype, family history of dementia, and subjective and objective measures of cognition, walking duration and sleep behavior, was validated in the independent Rotterdam Study with higher accuracy (AUC = 0.85 [0.81–0.89]). Yet, the improvement relative to a model including only age and APOE ε4 was marginal.DISCUSSIONAβ prediction models including inexpensive and non‐invasive measures were successfully applied to a general population–derived sample more representative of typical older non‐demented adults.